A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Resminostat (Primary)
- Indications Hodgkin's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms SAPHIRE
- Sponsors 4SC
- 02 Dec 2016 Results of biomarker analysis from SHELTER,SAPHIRE and SHORE trials presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 06 May 2014 Results published in an 4SC media release.
- 15 Jun 2013 Planned number of patients changed from 33 to 45 as reported by European Clinical Trials Database.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History